S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

EWTX Edgewise Therapeutics Inc

16.17

0.23 (1.44%)

27 Apr 2024 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

null

Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more Edgewise Therapeutics Charts.

Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Apr 2023 to Apr 2024

Click Here for more Edgewise Therapeutics Charts.

Edgewise Therapeutics Inc News

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
Tuesday 23 April 2024 (5 days ago) • Business Wire

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
Tuesday 16 April 2024 (2 weeks ago) • Business Wire

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
Thursday 28 March 2024 (1 month ago) • Business Wire

Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
Wednesday 27 March 2024 (1 month ago) • Business Wire

Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
Wednesday 6 March 2024 (2 months ago) • Business Wire

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
Thursday 29 February 2024 (2 months ago) • Business Wire

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Friday 23 February 2024 (2 months ago) • Business Wire

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Thursday 15 February 2024 (2 months ago) • Edgar (US Regulatory)

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
Wednesday 14 February 2024 (2 months ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 10 February 2024 (3 months ago) • Edgar (US Regulatory)

More Edgewise Therapeutics Inc News Articles

Commonwealth Bank Of Aus...

JP Morgan Chase

Gold vs US Dollar

Newcrest Mining

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions